Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Moderate Buy” by Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA) has been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $28.25.

BMEA has been the topic of a number of research analyst reports. Truist Financial downgraded Biomea Fusion from a “buy” rating to a “hold” rating in a report on Tuesday, June 11th. Piper Sandler dropped their price target on Biomea Fusion from $45.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, June 7th. JPMorgan Chase & Co. boosted their price target on Biomea Fusion from $14.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Scotiabank dropped their price target on Biomea Fusion from $41.00 to $21.00 and set a “sector outperform” rating on the stock in a research report on Friday, June 7th. Finally, Citigroup lowered their price objective on Biomea Fusion from $90.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, June 7th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Biomea Fusion by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,339,428 shares of the company’s stock valued at $18,431,000 after acquiring an additional 21,835 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Biomea Fusion by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,248 shares of the company’s stock valued at $134,000 after buying an additional 2,345 shares during the period. Griffin Asset Management Inc. acquired a new stake in Biomea Fusion in the fourth quarter valued at approximately $395,000. China Universal Asset Management Co. Ltd. boosted its stake in Biomea Fusion by 348.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,131 shares of the company’s stock valued at $60,000 after acquiring an additional 3,210 shares in the last quarter. Finally, Grove Bank & Trust acquired a new stake in Biomea Fusion in the fourth quarter valued at approximately $56,000. Institutional investors own 96.72% of the company’s stock.

Biomea Fusion Trading Down 2.2 %

BMEA opened at $5.45 on Friday. The company has a market cap of $195.87 million, a P/E ratio of -1.53 and a beta of -0.53. The business’s 50-day moving average price is $7.00 and its 200-day moving average price is $12.16. Biomea Fusion has a 12 month low of $3.61 and a 12 month high of $23.03.

Biomea Fusion (NASDAQ:BMEA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.07). Equities research analysts forecast that Biomea Fusion will post -4.09 earnings per share for the current fiscal year.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.